We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
WST's HVP components business grew 20% organically in Q3, led by GLP-1 and non-GLP-1 demand.
More than 200 regulatory-driven upgrade projects and expanding biologics exposure support multiyear growth.
West Vantage weakness, SmartDose 3.5 divestiture and pricing normalization pose challenges to future growth.
West Pharmaceutical Services, Inc. (WST - Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding biologics exposure and regulatory-driven Annex 1 conversions. Tariff pressures and weak results at West Vantage, where a cyber incident weighed on performance, remain concerns.
Shares of this Zacks Rank #2 (Buy) company have gained 46.9% year to date compared with the industry's 22% growth. The S&P 500 Index has risen 6% in the same time frame.
West Pharmaceutical, with a market capitalization of $28.85 billion, is a leading global manufacturer that designs and produces integrated containment and delivery systems for injectable drugs and other healthcare products. Its earnings are anticipated to improve 17.4% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 18.6%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s Prospects
Strong HVP Components Demand Across GLP-1 and Biologics: West Pharma's HVP components business remains its primary growth engine, benefiting from robust demand across GLP-1 therapies and non-GLP-1 applications. The business grew 20% organically in the third quarter, with non-GLP-1 HVP components increasing at a high-teens rate and GLP-1-related components growing well into the 30s.
HVP components now account for 53% of company revenues, highlighting their growing contribution to the business. The expanding biologics pipeline and increasing adoption of injectable therapies provide additional opportunities. With demand extending beyond GLP-1s, West Pharma's growth profile appears increasingly diversified across multiple pharmaceutical categories.
Regulatory-Driven HVP Upgrades Offer Growth Opportunity: Increasing regulatory requirements around contamination control are creating a favorable demand environment for West Pharma's high-value components. European Annex 1 regulations have already encouraged pharmaceutical manufacturers to upgrade their containment systems, while similar regulatory developments in the United States and other regions could broaden adoption. West Pharma added more than 200 upgrade projects during the year and views these opportunities as a multiyear growth driver.
These upgrades involve replacing existing components with higher-value solutions rather than necessarily increasing unit volumes. This could help West Pharma grow revenues, improve its sales mix and strengthen relationships with pharmaceutical customers.
HVP Delivery Devices Provide an Additional Growth Platform: West Pharma's HVP delivery device portfolio is demonstrating strong underlying momentum, supported by demand for Crystal Zenith and Administration Systems. Third-quarter organic revenues in this category increased 26% after excluding the SmartDose 3.5 divestiture and currency effects.
Management emphasized that growth came from multiple customers and markets, suggesting broader demand for West Pharma’s delivery systems across pharmaceutical applications. Continued development of self-injection devices such as SmartDose 10 could expand the company’s portfolio and help it meet growing demand for treatments patients can administer themselves.
Challenges for WST
West Vantage's Legacy Program Roll-Off: West Vantage continues to weigh on West Pharma’s overall revenue growth as the company shifts from lower-value legacy programs to higher-value drug-handling solutions.The segment's organic revenues declined 6.6% in the third quarter, primarily reflecting the roll-off of a continuous glucose monitoring (CGM) program, which more than offset contributions from new programs.
Management expects this transition to continue muting segment growth this year and next, even as new contracts ramp up. Although the strategic shift could improve the segment's long-term business mix, the timing gap between discontinued programs and replacement revenues creates near-term uncertainty around West Vantage's recovery.
SmartDose 3.5 Divestiture Creates a Reported Growth Headwind: The divestiture of SmartDose 3.5 creates a meaningful headwind to West Pharma's reported revenue growth in the coming year. The business generated approximately $100 million in revenues during 2026,until its divestment, but West Pharma does not expect further revenue contributions following the transaction.
Management indicated that the absence of SmartDose 3.5 will create an approximately 290-basis-point headwind to reported organic growth calculations in 2027. Although the divestiture allows West Pharma to focus on its core proprietary products and higher-value opportunities, the loss of this revenue stream could make headline growth comparisons less favorable despite continued underlying demand.
Normalization in Pricing and Potentially Slower HVP Device Growth: West Pharma benefited from a pricing contribution of over four percentage points to the third-quarter organic revenue growth, but management indicated that its long-term pricing assumption remains approximately 2-3%. Pricing may contribute less to revenue growth in the coming periods than it did in 2026.
Additionally, management cautioned that HVP delivery device growth could moderate in the fourth quarter because the business can be lumpy and faces a strong prior-year comparison. These factors could make it harder to sustain the exceptional growth rates recorded in the third quarter. Consequently, future performance will increasingly depend on underlying volume expansion, new program adoption and continued product upgrades.
West Pharmaceutical Services, Inc. Price and Consensus
WST has been witnessing a stable estimate revision for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings improved 4.9% to $9.37 per share, implying a gain of 28.5% from the prior-year reported level. The consensus mark for revenues is pegged at $3.41 billion, indicating an 11% increase from the 2025 reported level.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%.
Cardinal Health, currently carrying a Zacks Rank of 2, reported a first-quarter fiscal 2027 adjusted EPS of $3.26, which surpassed the Zacks Consensus Estimate by 11.64%. Revenues of $67.51 billion beat the Zacks Consensus Estimate by 0.8%.
CAH has an estimated long-term earnings growth rate of 10.1%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 13.79%.
Image: Bigstock
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding biologics exposure and regulatory-driven Annex 1 conversions. Tariff pressures and weak results at West Vantage, where a cyber incident weighed on performance, remain concerns.
Shares of this Zacks Rank #2 (Buy) company have gained 46.9% year to date compared with the industry's 22% growth. The S&P 500 Index has risen 6% in the same time frame.
West Pharmaceutical, with a market capitalization of $28.85 billion, is a leading global manufacturer that designs and produces integrated containment and delivery systems for injectable drugs and other healthcare products. Its earnings are anticipated to improve 17.4% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 18.6%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s Prospects
Strong HVP Components Demand Across GLP-1 and Biologics: West Pharma's HVP components business remains its primary growth engine, benefiting from robust demand across GLP-1 therapies and non-GLP-1 applications. The business grew 20% organically in the third quarter, with non-GLP-1 HVP components increasing at a high-teens rate and GLP-1-related components growing well into the 30s.
HVP components now account for 53% of company revenues, highlighting their growing contribution to the business. The expanding biologics pipeline and increasing adoption of injectable therapies provide additional opportunities. With demand extending beyond GLP-1s, West Pharma's growth profile appears increasingly diversified across multiple pharmaceutical categories.
Regulatory-Driven HVP Upgrades Offer Growth Opportunity: Increasing regulatory requirements around contamination control are creating a favorable demand environment for West Pharma's high-value components. European Annex 1 regulations have already encouraged pharmaceutical manufacturers to upgrade their containment systems, while similar regulatory developments in the United States and other regions could broaden adoption. West Pharma added more than 200 upgrade projects during the year and views these opportunities as a multiyear growth driver.
These upgrades involve replacing existing components with higher-value solutions rather than necessarily increasing unit volumes. This could help West Pharma grow revenues, improve its sales mix and strengthen relationships with pharmaceutical customers.
HVP Delivery Devices Provide an Additional Growth Platform: West Pharma's HVP delivery device portfolio is demonstrating strong underlying momentum, supported by demand for Crystal Zenith and Administration Systems. Third-quarter organic revenues in this category increased 26% after excluding the SmartDose 3.5 divestiture and currency effects.
Management emphasized that growth came from multiple customers and markets, suggesting broader demand for West Pharma’s delivery systems across pharmaceutical applications. Continued development of self-injection devices such as SmartDose 10 could expand the company’s portfolio and help it meet growing demand for treatments patients can administer themselves.
Challenges for WST
West Vantage's Legacy Program Roll-Off: West Vantage continues to weigh on West Pharma’s overall revenue growth as the company shifts from lower-value legacy programs to higher-value drug-handling solutions.The segment's organic revenues declined 6.6% in the third quarter, primarily reflecting the roll-off of a continuous glucose monitoring (CGM) program, which more than offset contributions from new programs.
Management expects this transition to continue muting segment growth this year and next, even as new contracts ramp up. Although the strategic shift could improve the segment's long-term business mix, the timing gap between discontinued programs and replacement revenues creates near-term uncertainty around West Vantage's recovery.
SmartDose 3.5 Divestiture Creates a Reported Growth Headwind: The divestiture of SmartDose 3.5 creates a meaningful headwind to West Pharma's reported revenue growth in the coming year. The business generated approximately $100 million in revenues during 2026,until its divestment, but West Pharma does not expect further revenue contributions following the transaction.
Management indicated that the absence of SmartDose 3.5 will create an approximately 290-basis-point headwind to reported organic growth calculations in 2027. Although the divestiture allows West Pharma to focus on its core proprietary products and higher-value opportunities, the loss of this revenue stream could make headline growth comparisons less favorable despite continued underlying demand.
Normalization in Pricing and Potentially Slower HVP Device Growth: West Pharma benefited from a pricing contribution of over four percentage points to the third-quarter organic revenue growth, but management indicated that its long-term pricing assumption remains approximately 2-3%. Pricing may contribute less to revenue growth in the coming periods than it did in 2026.
Additionally, management cautioned that HVP delivery device growth could moderate in the fourth quarter because the business can be lumpy and faces a strong prior-year comparison. These factors could make it harder to sustain the exceptional growth rates recorded in the third quarter. Consequently, future performance will increasingly depend on underlying volume expansion, new program adoption and continued product upgrades.
West Pharmaceutical Services, Inc. Price and Consensus
West Pharmaceutical Services, Inc. price-consensus-chart | West Pharmaceutical Services, Inc. Quote
Estimate Trend
WST has been witnessing a stable estimate revision for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings improved 4.9% to $9.37 per share, implying a gain of 28.5% from the prior-year reported level. The consensus mark for revenues is pegged at $3.41 billion, indicating an 11% increase from the 2025 reported level.
Other Key Picks
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%.
Cardinal Health, currently carrying a Zacks Rank of 2, reported a first-quarter fiscal 2027 adjusted EPS of $3.26, which surpassed the Zacks Consensus Estimate by 11.64%. Revenues of $67.51 billion beat the Zacks Consensus Estimate by 0.8%.
CAH has an estimated long-term earnings growth rate of 10.1%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 13.79%.